The QualityStocks Daily Friday, March 17th, 2023

Today's Top 3 Investment Newsletters

MarketClub Analysis(ENZ) $2.2500 +89.08%

QualityStocks(SNCE) $0.3570 +58.10%

InvestorPlace(CMCL) $16.6600 +17.82%

The QualityStocks Daily Stock List

Enzo Biochem (ENZ)

Ceocast News, StreetInsider, Wall Street Resources, PennyOmega, CRWEPicks, CRWEWallStreet, SmarTrend Newsletters, DrStockPick, StockHotTips, CRWEFinance, PennyToBuck,, MarketBeat, BestOtc, Weekly Market Strategies, Zacks, StockMarketWatch, The Street, Top Pros' Top Picks, SmallCapVoice, StockOodles, Street Insider, BUYINS.NET, Micro Cap Momentum, Barchart, Stockhouse, InvestorGuide, INO Market Report, InvestorPlace, Market FN, MarketClub Analysis, AnotherWinningTrade, QualityStocks, Stock Research Newsletter, StocksEarning, Super Stock Picker, The Best Newsletters, Today's Financial News, TradersPro and PennyTrader Publisher reported earlier on Enzo Biochem (ENZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Enzo Biochem, Inc. (NYSE: ENZ) (FRA: EZB) is an integrated clinical lab and diagnostics life firm that is engaged in researching, developing, manufacturing and marketing diagnostic and research products based off of molecular biology, biotechnology and genetic engineering.

The firm has its headquarters in New York and was incorporated in 1976 by Shahram K. Rabbani, Barry W. Weiner and Elazar Rabbani. It operates in the health care sector, under the health care facilities and services sub-industry and markets its products across the globe.

The company operates through the Therapeutics, Life Sciences products and Clinical Lab services segments. The latter segment involves the provision of various clinical services to medical centers, physicians, pharmaceutical firms and other clinical labs while the therapeutics segment is engaged in the development of multiple new approaches in the areas of metabolic, ophthalmic, infectious and gastrointestinal ailments. On the other hand, the life sciences segment is focused on developing, manufacturing and marketing tools and products for bioscience research, drug development and clinical research customers internationally. The company generates the majority of its revenue from the clinical laboratory segment.

The enterprise’s products include kits, dyes, labeling probes, small molecules, peptides, antibodies and proteins that offer life sciences researchers tools for cellular analysis, protein detection and biochemistry, nucleic acid detection, gene expression analysis, content analysis and target validation/identification. It markets its products via a network of distributors in the U.S. and internationally as well as via its direct sales force.

The firm recently entered into a collaboration to offer rapid access to coronavirus PCR testing in the states of New Jersey and New York via its TrustAssure Global Network. This convenient resource will not only make it easier for consumers to meet testing requirements and make sure they have a safe travel experience but also bring in more investments into the firm, which will in turn boost the firm’s growth.

Enzo Biochem (ENZ), closed Friday's trading session at $2.25, up 89.0756%, on 36,143,742 volume. The average volume for the last 3 months is 3.734M and the stock's 52-week low/high is $1.00/$3.19.

Science 37 (SNCE)

QualityStocks and MarketBeat reported earlier on Science 37 (SNCE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Science 37 Holdings Inc. (NASDAQ: SNCE) is a holding firm focused on developing a technology platform to plan clinical trials and allow specialized networks to execute trials.

The firm has its headquarters in Research Triangle Park, North Carolina and was incorporated in 2014. Prior to its name change in October 2021, the firm was known as Science 37 Inc. It operates as part of the scientific research and development services industry, under the healthcare sector. The firm has four companies in its corporate profile and serves consumers in the United States.

The company develops innovative and new treatments which impact patients’ lives by enabling universal access to providers for clinical trials. Its operating system is made up of networks of patient communities, remote coordinators, mobile nurses, telemedicine researchers and connected devices.

The enterprise’s platform provides extensive configuration to support any phase of clinical study and any indication. Its offerings include Study Configuration and Diversity & Inclusion, Technology+, Metasite and Fully DTC. The enterprise also licenses its hosted technology platform to a number of life science institutions. Its consumer base is comprised of biotechnology firms, academic and governmental institutions, contract research organizations, mid-sized and large pharmaceutical firms and medical device companies.

The firm recently released its latest financial results, which show a significant increase in the firm’s revenues. Its CEO noted that the firm was well positioned to deliver on its objectives, which will benefit its shareholders and drive up investments into the firm.

Science 37 (SNCE), closed Friday's trading session at $0.357, up 58.1045%, on 3,771,076 volume. The average volume for the last 3 months is 50.813M and the stock's 52-week low/high is $0.19/$6.51.

Histogen (HSTO)

QualityStocks, MarketBeat, The Online Investor, PennyStockProphet and InvestorPlace reported earlier on Histogen (HSTO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Histogen Inc. (NASDAQ: HSTO) (FRA: CPH1) is a regenerative medicine firm that is engaged in the development of potential first-in-class restorative therapies that stimulate the natural process of the body to regenerate and replace tissues.

The firm has its headquarters in San Diego, California and was founded in 2005, on July 13th by Gail K. Naughton and Steven J. Mento. It operates in the health care sector under the biotech and pharma sub-industry. Prior to its name change, the firm, which serves consumers in the state of California, was known as Conatus Pharmaceuticals Inc.

The company’s innovative technology platform uses extracellular matrix materials which have been produced by multipotent cells that are hypoxia induced and cell-conditioned media to develop therapies that address various multi-billion dollar international markets.

The enterprise is centered on Hair Stimulating Complex, Human Extracellular Matrix and Human Multipotent Cell Conditioned Media. It has product candidates currently in clinical development which have been designed to provide treatments for joint cartilage repair, dermal filler and hair loss. In addition to this, the enterprise manufactures an insoluble ECM (extracellular matrix) for applications such as soft tissue augmentation, wound care and orthopedics. This is in addition to manufacturing a soluble multipotent CCM (cell conditioned media), which is used as a starting material for products for skin care and hair growth, among other applications.

The firm recently announced an update on its pipeline focus after a strategic evaluation of its regenerative medicine development programs. Its objective is to maximize its resources in an attempt to further drive long-term shareholder value. This move is bound to bring in more investors into the firm.

Histogen (HSTO), closed Friday's trading session at $1.33, up 54.2387%, on 50,812,676 volume. The average volume for the last 3 months is 80,647 and the stock's 52-week low/high is $0.7603/$9.40.

Moolec Science (MLEC)

The Stock Dork and 360wallstreet reported earlier on Moolec Science (MLEC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Moolec Science SA (NASDAQ: MLEC) is a science-based food ingredient firm focused on the development of real animal proteins in plants using molecular farming.

The firm has its headquarters in Luxembourg and was incorporated in 2022, on May 23rd by Martin Salinas, Henk Hoogenhamp and Gastón Paladini. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the world.

The company has developed a disruptive technology in the alternative protein landscape, whose purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. This technology allows it to include animal proteins' gene deoxyribonucleic acid (DNA) codes inside the genome of the main plants used in food. The company’s approach is cost-effective and environmentally friendly by consuming fewer resources through biology.

The enterprise’s offerings include a dairy ingredient dubbed Chymosin SPC; GLA SONOVA, a nutritional oil; and a meat replacement product known as BEEF+. It also offers POORK+, a plant-based, animal meat-free ingredient with porcine proteins in soybeans. The enterprise operates in the United States, Europe and South America.

The firm recently began trading on the NASDAQ, which is a huge accomplishment, given that it is the first of its kind to be listed on the exchange. This move will greatly influence its growth and expansion, in addition to increasing its visibility and access to global capital markets. This will in turn extend its consumer reach and generate value for its shareholders.

Moolec Science (MLEC), closed Friday's trading session at $4.8, off by 2.0408%, on 80,647 volume. The average volume for the last 3 months is 191,963 and the stock's 52-week low/high is $4.35/$42.25.

Neuronetics (STIM)

MarketBeat, StockMarketWatch, TradersPro, StockEarnings, Zacks, StreetInsider, InvestorPlace and BUYINS.NET reported earlier on Neuronetics (STIM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Neuronetics Inc. (NASDAQ: STIM) (FRA: NRC) is a commercial-stage medical technology firm that is focused on designing, developing and marketing products for patients with neurohealth disorders.

The firm has its headquarters in Malvern, Pennsylvania and was incorporated in April 2003 by Thomas D. Weldon, Norman R. Weldon, Bruce J. Shook and Steven B. Waite. It operates as part of the diagnostics and research industry, under the healthcare sector. The firm serves patients around the world, with a focus on those in the United States.

The company is focused on improving the quality of life for patients who suffer from psychiatric disorders. Its primary focus is on selling to psychiatrists, as well as primary care physicians and pain management specialists. The company operates through the United States and International geographical segments.

The enterprise’s offerings include a non-invasive and non-systemic office-based treatment dubbed the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy platform and system was designed as a therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

The firm recently announced its latest financial results, which show increases in its treatment session and advanced therapy revenues. It remains focused on fueling its growth, which will positively influence investments into the firm and help create shareholder value.

Neuronetics (STIM), closed Friday's trading session at $2.83, off by 4.3919%, on 191,963 volume. The average volume for the last 3 months is 191,298 and the stock's 52-week low/high is $1.98/$6.9522.

Kinnate Biopharma (KNTE)

MarketBeat, StreetInsider and FreeRealTime reported earlier on Kinnate Biopharma (KNTE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kinnate Biopharma Inc. (NASDAQ: KNTE) (FRA: 6KB) is a biopharmaceutical firm focused on discovering and developing small molecule kinase inhibitors for the treatment of genomically defined cancers.

The firm has its headquarters in San Francisco, California and was incorporated in January 2018 by Eric A. Murphy and Stephen W. Kaldor. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company’s mission is to inspire hope for those battling cancer by expanding on the promise of targeted therapies. It is driven by the urgency and knowledge that patients are waiting for new, effective cancer medicines. The company uses its expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which the company refers to as the Kinnate Discovery Engine, to develop targeted therapies.

The enterprise’s pipeline is comprised of KIN-2787, a rapidly accelerated fibrosarcoma (RAF) inhibitor developed for the treatment of patients suffering from lung cancer, melanoma, and other solid tumors; and KIN-3248 small-molecule kinase inhibitors, which target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes. It also has small molecule research programs, which include Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program.

The firm recently received Fast Track designation from the FDA for its KIN-3248 inhibitor, for the treatment of patients with unresectable, locally advanced or metastatic cholangiocarcinoma. The success and approval of this formulation will not only benefit patients with this indication but also boost investments into the firm.

Kinnate Biopharma (KNTE), closed Friday's trading session at $5.42, off by 0.732601%, on 196,481 volume. The average volume for the last 3 months is 1.175M and the stock's 52-week low/high is $3.30/$15.86.

Brightcove (BCOV)

All about trends, Money Morning, MarketBeat, The Street, StreetInsider, MissionIR, StreetAuthority Daily, Hit and Run Candle Sticks, TradersPro, National Inflation Association,,, Zacks, StockMarketWatch, Schaeffer's, Rick Saddler, TopStockAnalysts, Daily Trade Alert, InsiderTrades, Barchart, CustomerService, Wall Street Mover, Wall Street Daily, InvestorPlace, Stocks That Move, MarketClub Analysis, Trades Of The Day, Tiny Gems and Investing Futures reported earlier on Brightcove (BCOV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Brightcove Inc. (NASDAQ: BCOV) (FRA: 2BV) is a company engaged in the provision of cloud-based streaming services.

The firm has its headquarters in Boston, Massachusetts and was incorporated in August 2004 by Robert Mason and Jeremy J. Allaire. It operates as part of the software-application industry, under the technology sector. The firm serves consumers around the globe, generating a majority of its revenue from Asia and North America.

The enterprise’s flagship product includes Video Cloud, an online video streaming platform that enables its customers to distribute high-quality video to internet-connected devices. It also offers Brightcove Player, a cloud-based technology for creating and managing video experiences; Brightcove Live, a solution for live streaming; and Brightcove Beacon, an application that enables companies to launch over-the-top video experiences of multiple monetization models. The enterprise also provides a cloud-based video encoding technology dubbed Zencoder; Brightcove Audience Insights, a business intelligence platform that provides actionable intelligence on viewers and subscribers. In addition to this, it offers a range of video solutions, including Brightcove Virtual Events, a platform for customers to create bespoke, immersive live and always-on virtual experiences; and Brightcove CorpTV, an application that enables marketing videos, product announcements, training programs, and other live and on-demand content. The enterprise serves media, publishers, broadcasters,sports and entertainment companies, fashion, retail and e-commerce platforms, faith-based institutions, and hi-tech organizations, governments, educational institutions, and hospitality brands.

The company recently introduced new integrations with Shopify, Instagram and Salesforce Sales Cloud to its video cloud platform. This move to expand its e-commerce capabilities will allow it to better meet consumer needs, while also generating additional revenue for the company.

Brightcove (BCOV), closed Friday's trading session at $4.37, off by 4.1667%, on 1,175,181 volume. The average volume for the last 3 months is 3.218M and the stock's 52-week low/high is $4.285/$8.13.

Hudbay Minerals (HBM)

MarketBeat, InvestorPlace,, Streetwise Reports, StreetInsider, Zacks, Schaeffer's, Daily Trade Alert, MarketClub Analysis, Trades Of The Day, Cabot Wealth,, DividendStocks, Super Stock Picker, The Street, BUYINS.NET, Stockhouse, Investiv, Investopedia, QualityStocks, AllPennyStocks, ProfitableTrading, StockMarketWatch, StreetAuthority Daily, The Growth Stock Wire, TradersPro and reported earlier on Hudbay Minerals (HBM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hudbay Minerals Inc. (NYSE: HBM) (TSE: HBM) (FRA: OCKA) (LON: 0AHJ) is a diversified mining firm focused on exploring for, developing, operating and optimizing mineral properties in North and South America.

The firm has its headquarters in Toronto, Canada and was incorporated in 1996, on January 16th. It operates as part of the copper industry, under the basic materials sector. The firm serves consumers around the globe.

The company primarily mines and produces copper concentrates containing copper, gold, and silver; silver/gold doré and zinc metals; and molybdenum concentrates. It operates through its subsidiaries, which include HudBay Marketing & Sales Inc., HudBay Peru Inc., HudBay Peru S.A.C., HudBay (BVI) Inc., Hudbay Arizona Inc, Rosemont Copper Company and Mason Resources (US) Inc. The company generates the majority of its revenue from its copper business.

The enterprise owns three polymetallic mines, four ore concentrators, and a zinc production facility in northern Manitoba and Saskatchewan, Canada, as well as in Cusco, Peru; and copper projects in Arizona and Nevada, in the United States. It sells copper concentrates to smelters across Asia, America, and Europe; and sells Zinc metal, the next biggest source of revenue, to industrial customers across North America.

The company recently announced its latest financial results, with its CEO noting that they were focused on generating free cash flow by increasing production of copper and gold and unlocking value from its pipeline of organic growth opportunities. This will, in turn, bolster the company’s overall growth and create value for its shareholders.

Hudbay Minerals (HBM), closed Friday's trading session at $4.55, up 2.4775%, on 3,217,984 volume. The average volume for the last 3 months is 222,582 and the stock's 52-week low/high is $3.08/$8.285.

Bit Mining Ltd. (BTCM)

QualityStocks, MarketClub Analysis, Schaeffer's, StockEarnings, Wall St. Warrior, The Stock Dork, StocksEarning, smartmoneytrading, MarketBeat, INO Market Report and 247 Market News reported earlier on Bit Mining Ltd. (BTCM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Two banks that had warmed up to crypto and supported tech startups have buckled in under a week. In a welcome move, crypto prices rallied over the weekend when the federal government came in to guarantee depositors’ funds in the two banks.

Silvergate Capital, which is a cryptocurrency central lender, announced on Wednesday that it is closing its operations and liquidating. The Silicon Valley Bank, a lender to most technology startups, crashed on Friday after depositors panicked and cashed out more than $42 billion after the bank announced its need to raise $2.25 billion to balance its books. Signature, a much larger entity than Silvergate, had a notable crypto focus and was taken over by banking regulators on Sunday.

Silvergate and Signature are the two major banks favored by crypto companies, and most U.S. venture startups banked with Silicon Valley Bank, including some digital asset enterprises as well as crypto affiliate venture capital funds. The federal government came in over the weekend to cover all SVB and Signature client deposits, boosting confidence and causing a little uptick within the crypto markets. Bitcoin and Ether shot up by 10% within the next 24 hours.

Castle Island Ventures’ Nic Carter points out that the willingness of the government to shore up these banks proves that the government is back to providing liquidity and resuming the monetary policies that have aided cryptocurrencies and other asset classes.


Many of last year’s crypto issues emanated from the stablecoin sector, and TerraUSD was the first to collapse last May. During the weekend, the stablecoin sector was hit again as USDC dropped below 87 cents when the issuer, Circle, confessed to banking some $3.3 billion with SVB. DAI, another virtual currency, traded at 90 cents. These events prompted some traders to swap their USDC and DAI to acquire tether whose market value stands above $72B. The stablecoin market gained ground after Circle published a blog post on Sunday saying it will take responsibility for any shortfalls using corporate resources.

Mike Bucella, an executive and crypto investor, says many within the industry are circling toward Mercury and Axos, the other two banks catering for startups. Circle has gone public declaring its shift to BNY because of the imminent closure of Signature Bank.

It is tough for crypto banking within the North American space, but there are challenger banks willing to pick up the slack, says Bucella. Industry players such as Bit Mining Ltd. (NYSE: BTCM) would be relieved if normalcy returns to the crypto space in the wake of the collapse of these major banks serving blockchain clients.

Bit Mining Ltd. (BTCM), closed Friday's trading session at $2.2, off by 2.6549%, on 243,963 volume. The average volume for the last 3 months is 342,154 and the stock's 52-week low/high is $1.40/$31.755.

Compass Pathways PLC (CMPS)

QualityStocks, InvestorBrandNetwork, InvestorPlace, MarketBeat, Daily Trade Alert, StreetInsider, Schaeffer's, Trades Of The Day and The Street reported earlier on Compass Pathways PLC (CMPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A microbiome is a group of up to 1,000 microbial and bacterial species that live within your body and play a major role in a variety of functions. Most of the microorganisms in the microbiome are symbiotic and have mutually beneficial relationships with their host. In recent years, increased research into the human microbiome has indicated that it plays a critical role in maintaining both physical and mental health.

As the field of psychedelic research picks up speed amid a surge of investment into hallucinogenic drug research, more scientists are considering the association between psychedelics and the human microbiome. Several studies involving psychedelic drugs, including psilocybin, ketamine and MDMA, have revealed that they are capable of producing profound and long-lasting health benefits at minimal doses and with relatively few side effects.

While scientists still aren’t entirely sure how psychedelics act on the body to produce these effects, plenty of researchers are currently studying how psychedelic compounds can have such profound effects on consciousness. Maastricht University’s Dr. Kim Kuypers began looking into the relationship between microbiomes and psychedelics in 2019. She wanted to understand why the effects of psychedelics tend to last long after the actual trip is over, and she thought that the body’s microbiome may play a role.

Kuypers said that psychedelic research is a new field, and most scientists tend to focus on the cognitive or psychological effects of psychedelics in their studies. While the gut microbiome may indeed play a role in how psychedelics affect the user, studying this relationship is a pretty tedious task.

There are billions of fungi and bacteria living in the gut and their interactions, which are practically innumerable, often have a varied range of effects on different biological systems within the body. But one link shared between the gut microbiome and psychedelics is that they both affect physical and mental health.

Trinity College’s Dr. John Kelly is also keen on understanding the microbiome’s complexities and how it is affected by psychedelic drugs. In a recent study, Kelly suggests that microbiome interventions could be made during the preparation and integration phases to make psychedelic treatment more effective. He described how certain combinations of psychedelic compounds and microbes could interact in vastly different ways as the microbiome communicates with the body in a wide array of pathways.

Kelly posited that the microbiome essentially acts as an interface between the environment and “the self” and that it could be harnessed during psychedelic treatment to help bring a patient into a “healthier homeostatic state.” However, significantly more research will be needed to ascertain the link between gut bacteria and psychedelics and how this association can be used to make psychedelic-assisted therapy more effective.

With all the psychedelic research being undertaken by entities such as Compass Pathways PLC (NASDAQ: CMPS), the world is likely to learn plenty more about these fascinating hallucinogens.

Compass Pathways PLC (CMPS), closed Friday's trading session at $8.33, off by 4.0323%, on 342,286 volume. The average volume for the last 3 months is 4.189M and the stock's 52-week low/high is $6.54/$21.50.

Lordstown Motors Corp. (RIDE)

Green Car Stocks, Schaeffer's, InvestorPlace, QualityStocks, StocksEarning, The Street, StockEarnings, MarketBeat, MarketClub Analysis, Trades Of The Day, Early Bird, Daily Trade Alert, The Online Investor, CNBC Breaking News, Investopedia, GreenCarStocks, Kiplinger Today, StreetInsider, BUYINS.NET, The Stock Dork and Cabot Wealth reported earlier on Lordstown Motors Corp. (RIDE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The 2023 UK Vehicle top accolade has been given to an electric vehicle. The judges praised the vehicle as “excellent” and said that it was reasonably priced. A significant victory for electric automobiles was achieved with the selection of the MG4 as the winner in the UK car contest.

The MG4 was declared the ultimate winner out of seven new vehicles on the final list, placing it ahead of Dacia, Lotus, Land Rover and Kia, as well as Toyota cars. The closest rivals for the MG4 were models with IC engines, in contrast to the previous year, when the leading four vehicles were electric powered.

The MG4 is living proof that electric vehicles can be pragmatic, economical and appealing to all segments of the car market. When on full charge, it provides adequate mileage up to 281 miles for the majority of trips, featuring a remarkable aesthetic and design as well as driving characteristics that meet two other crucial criteria for customers: the MG4 charges super fast and has a starting price of only £26,995 ($32,655).

The seven-seater Dacia Jogger was a deserving runner-up, and Toyota’s GR86, which won the 2023 Best Coupé title, took third place. This Dacia Jogger, which starts at a reasonable £17,175 ($20,776), was praised for emphasizing economical driving.

The SUV too is available in a hybrid model, which may cost £30 less than its petrol equivalent and offers drivers a complimentary initial service as well as controlled media and speed control.

In the end, the MG4 defeated the other six competitors by a wide margin to win the UK Vehicle of the Year award. While receiving the trophy for the winner, Guy Pigounakis was ecstatic about the triumph. He stated that since the release of MG4 in September last year, it has proven to be popular both with current and potential consumers. It is also quite reassuring that a lot of professional reviews share this opinion. He then thanked everyone present for the award, which he described as a major accomplishment for MG. The MG4 received high praise from the panel of 27 judges for the UK’s 2023 Top Car Awards.

According to Jonny Smith, the MG4 accomplishes every task better than what anyone might have anticipated given its cost. The MG4 was dubbed the vehicle many other automakers would desire to have manufactured, according to Paul Barker, providing evidence that electric vehicles may be remarkably attractive while also being reasonably priced, useful and functional.

Those interested can view the detailed list of 2023 UK vehicle of the year winners category.

This win in the United Kingdom is a win for the entire industry and the players therein such as Lordstown Motors Corp. (NASDAQ: RIDE) because it proves that EVs can outcompete conventional vehicles on all parameters of performance, safety, reliability and even cost.

Lordstown Motors Corp. (RIDE), closed Friday's trading session at $0.726, off by 5.8488%, on 4,189,055 volume. The average volume for the last 3 months is 12.638M and the stock's 52-week low/high is $0.705/$3.79.

Hecla Mining Company (HL)

MarketClub Analysis, SmarTrend Newsletters, Schaeffer's, InvestorPlace, Wyatt Investment Research, StocksEarning,, MarketBeat, QualityStocks, Top Pros' Top Picks, TopStockAnalysts, StreetAuthority Daily, Market Report, The Street, Money Morning, Zacks, Jason Bond,, Kiplinger Today, Daily Trade Alert, Today's Financial News, StreetInsider, Wall Street Grand, Trades Of The Day, TheStockAdvisors, Streetwise Reports, StockOodles, StockEarnings, Gryphon Digest, TradersPro, The Wealth Report, Penny Detectives, TradingAuthority Daily, National Inflation Association, SureMoney, Stockhouse, ChartAdvisor, INO Market Report, TraderPower, Options Elite, Wall Street Daily, The Growth Stock Wire, Penny Sleuth, Profit Confidential, ProfitableTrading, DividendStocks, Darwin Investing Network, PennyStockLive, Daily Markets, BestOtc, Barchart, Investing Futures, CRWEFinance, Investing Lab, CRWEPicks, Greenbackers, Forbes, DrStockPick, Daily Wealth, CustomerService, CRWEWallStreet, Rockwell Trading, Weiss Research, WealthMakers, Wealth Insider Alert, TradingMarkets, Traders For Cash Flow, Trade of the Week, The Online Investor, StockHotTips, PennyOmega, SmallCapVoice, Investopedia, Residual Income Report, PennyToBuck, AllPennyStocks, MonsterStocksPicks, Money and Markets,, InvestorGuide, Investor Update, Investor Guide and Stock Stars reported earlier on Hecla Mining Company (HL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The precious metals market experienced a boost amid a recent banking crisis that has seen three major banks become insolvent. Gold prices rose to more than $1,900 per ounce and nearly reached the $2,036 per ounce high seen in July 2020 in the wake of the third-biggest bank failure in America’s history.

After consecutive interest rate hikes by the U.S. Federal Reserve caused the value of Silicon Valley Bank’s investments in long-term, higher-yield, mortgage-backed bonds and securities bonds to plummet, the bank began scrambling to fill the large hole in its balance sheet. Efforts by the bank to offset the balance sheet by selling off assets failed, and the Federal Deposit Insurance Corp. seized SVB’s assets while customers withdrew their funds from the bank en-masse.

A few days later, regulators announced the closure of Signature Bank, which also had deep ties to big tech, much like SVB.

The turmoil in the banking sector supported gold and U.S. treasuries as the events triggered speculation of increasing credit event risk. As regulators begin to stress-test banking institutions to see if SVB’s problems were contained or will spread through the banking sector, more investors may choose to put their money in safe-haven assets such as gold and silver.

The recent collapse of SVB and Signature Bank mirrors the collapse of Lehman Brothers more than a decade ago, which played a central role in the development of the Great Recession. This collapse could trigger fears of an incoming recession and cause more funds to flow into safe-haven assets as investors seek to preserve the value of their holdings.

Precious metals have traditionally acted as safe-haven investments during times of economic upheaval because, unlike fiat currencies such as the dollar, their value remains steady regardless of economic upheaval. These metals

tend to see a surge of investor interest when markets falter and perform relatively well during economic downturns.

However, gold did not perform as well as expected in 2022, despite poor economic conditions as high-interest rates increased the opportunity cost of holding gold and encouraged investors to pour their funds into assets that pay interest.

Prices began to pick up in mid-2022 as central banks around the world stepped up their gold purchases and demand for gold among central banks remained high through the year and into 2023. With the recent turmoil in the banking industry, we can reasonably expect more funds to flow to the precious metals market, especially now that major banks such as SVB are collapsing and making it difficult for people to access their hard-earned funds.

Pure Gold Company CEO Josh Paul said that the crisis has left plenty of customers panicked and may encourage them to transfer their funds out of the banking system by buying physical gold.

As investors channel their funds to safe haven assets such as precious metals, entities operating in this space, such as Hecla Mining Company (NYSE: HL), will offer greater value to their shareholders despite the ongoing economic turmoil.

Hecla Mining Company (HL), closed Friday's trading session at $5.59, up 3.7106%, on 21,594,977 volume. The average volume for the last 3 months is 1,629 and the stock's 52-week low/high is $3.41/$7.3801.

The QualityStocks Company Corner

Progressive Care Inc. (OTCQB: RXMD)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (OTCQB: RXMD).

Progressive Care Inc. (OTCQB: RXMD) is a health services organization based in Florida that offers personalized healthcare services and technology that supports the managed healthcare industry. Through its subsidiaries, Progressive Care provides Third-Party Administration (TPA), data management and analytics, COVID-19 diagnostics and vaccinations, 340B contracted pharmacy services, compounded medications, tele-pharmacy services, dispensing of anti-retroviral medications, medication therapy management (MTM), long-term care facility-targeted prescription medications, and health practice risk management.

The company collaborates with various healthcare organizations such as managed care organizations (MCOs), management services organizations (MSOs), accountable care organizations (ACOs), primary care providers, Medicare Advantage plans, Medicaid, commercial payors, pharmaceutical manufacturers, and distributors to enhance patient and provider engagement while improving the lives of patients with chronic diseases. Progressive Care offers a wide range of innovative solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs.

Progressive Care currently operates four pharmacies in Florida, which generate the majority of its revenue. Pharmacy revenue is derived from dispensing medications, third-party administrative services to 340B-covered entities, and MTM services. The company also provides customized management, patient health risk reviews, and free same- and next-day delivery. Its focus is on complex chronic diseases that require multiyear or lifelong therapy, driving recurring revenue and sustainable growth. Progressive Care’s pharmacy revenue growth stems from its expanding breadth of services, new drugs coming to market, new indications for existing drugs, volume growth with current clients, and addition of new customers resulting from its emphasis on higher patient engagement, free delivery to the patient, and clinical expertise.

With licenses in 14 states, Progressive Care is poised for national expansion. The company anticipates revenue growth by signing new contract pharmacy service and data management contracts with 340B-covered entities, expanding data management and analytics services to healthcare organizations, and potential acquisitions.


Progressive Care’s wholly-owned subsidiaries provide services to client organizations and patients.

PharmcoRx Pharmacy

PharmcoRx, a full-service pharmacy, provides a complete healthcare ecosystem with services such as medication therapy management, rapid COVID-19 testing and vaccines, contactless medication delivery, Smart-Pack Unit Dosing packaging, custom compound medications, specialty medications, hospital transition pharmacy services, medication adherence monitoring, medication adherence risk management, and drug cost containment. PharmcoRx Pharmacy is a contracted pharmacy services provider for 340B-covered entities under the 340B Drug Discount Pricing Program.


ClearMetrX, a wholly-owned data management company, offers services that support healthcare organizations across the country. In September 2022, ClearMetrX launched the 340MetrX Platform, a software product developed by ClearMetrX that provides 340B-covered entities with data insights to effectively operate and maximize the benefits of the 340B program. 340MetrX supplies data access and delivers actionable insights that providers and support organizations can use to improve their practices and patient care. Its TPA services include management of wholesale accounts and contract pharmacies, patient eligibility with regard to the 340B drug program, development and review of 340B policies and procedures, and management of receivables.

Market Opportunity

According to an industry report by global consulting firm Berkeley Research Group, gross sales across the 340B drug program were valued at $116 billion in 2021 and are projected to grow to $280 billion by 2026, achieving a CAGR of more than 19% over the period.

The 340B drug pricing program allows eligible healthcare clinics and hospitals (the covered entities) to purchase outpatient drugs at a 20-50 percent discount to treat low-income, uninsured, or underinsured populations. The program’s forecast growth is expected to benefit Progressive care’s business of providing 340B program services to covered entities through the nationwide expansion of ClearMetrX, its third-party administration and data-management business.

Management Team

Charles M. Fernandez is CEO and Chairman of the Board of Directors of Progressive Care. Mr. Fernandez is also the Executive Chairman and CEO of NextPlat Corp. (NASDAQ: NXPL) and has over 30 years of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. In 2008, he joined Fairholme Capital Management. As president, he co-managed all three Fairholme funds and was commended for bringing in a $2 billion gain for shareholders. Throughout his impressive career in media, pharmaceuticals, healthcare, finance and technology, Mr. Fernandez has participated in more than 100 significant mergers, acquisitions and product development projects. He was the founder, chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK) which was successfully sold to Smartrac, a leading developer, manufacturer and supplier of RFID and Internet of Things (“IoT”) solutions and a unit of Avery Dennison Corporation (NYSE: AVY).

Other top management team members include Chief Operating Officer Birute Norkute, Chief Financial Officer Cecile Munnik, and Pamela Roberts, who serves as the company’s Pharmacist in Charge.

FingerMotion Inc. (RXMD), closed Friday's trading session at $4.33, off by 0.230415%, on 1,630 volume. The average volume for the last 3 months is 11,403 and the stock's 52-week low/high is $3.40/$10.40.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

The Japanese government recently announced that the coronaviruswill be categorized as a common infectious disease on May 8, 2023. As a result, patients diagnosed with the communicable disease willhave to cover medical expenses on their own. In the wake of the coronavirus pandemic in 2020, Japan’s government instituted a special response thatlimited the number of medical institutions that could handleCOVID-19 patients. The upcoming reclassification will classify thecoronavirus as a class 5 disease similar to conditions such as seasonal influenza. At the moment,Japan currently classifies COVID-19 as part of a special categorythat is equal to or stricter than class 2, which includesinfectious diseases, including severe acute respiratory syndrome (SARS) and tuberculosis. The government will seek to raise thenumber of medical institutions that can offer outpatient treatmentfor COVID-19 patients by 50%. It will also keep subsidizing theexpensive drugs used to fight coronavirus infection until the endof September 2023. Molnupiravir, for instance, which can cost up to 100,000 yen per outpatient($743), will be subsidized by the government while patients willhave to dig into their pockets to pay for general treatments suchas tests and antipyretics. The case burden of infectious diseasesis increasing around the world, and this creates some kind ofurgency for the new treatments that are being developed by biotechfirms such as BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) in order to reduce the human and economic toll of these diseases.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Friday's trading session at $2.34, up 1.2987%, on 11,965 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $10.40/$.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a technology company with a custom-developed Fr8App, anindustry-leading freight-matching platform powered by AI andmachine-learning that offers a real-time portal for B2Bcross-border shipping and domestic shipping within the USMCAregion. The company today announced the launch of its new brandFr8Now, a digital freight-matching platform that offersless-than-truckload (“LTL”) services in Mexico. With Fr8Now,Freight Technologies is marking its entry into the highlyfragmented and rapidly growing LTL market in Mexico, which has fewestablished players. “Our team has worked tirelessly to bringFr8Now operational,” said Javier Selgas, CEO of Fr8Tech. “With ournew platform firmly in place, we believe we are one of the firstcompanies in Mexico to offer LTL digital solutions. We areconfident that Fr8Now will be a game-changer for businesses lookingto ship goods both in-country in Mexico and from Mexico to theexterior. We offer a value-add to small businesses in Mexicoseeking economic product distribution as well as small carriersseeking local distribution routes - so it’s a win-win solution on anumber of fronts. These markets are already well developed in theU.S., but we believe they are at a nascent stage in Mexico.”

To view the full press release, visit

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.


Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Friday's trading session at $0.1932, up 1.6307%, on 397,324 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1799/$3.60.

Recent News

Utopia VR

The QualityStocks Daily Newsletter would like to spotlight Utopia VR

Utopia VR is one of the world’s first ‘Metaverse-As-A-Service’ solutions for business. The company’s hosted and managed subscription software provides businesses a low barrier to entry, browser-based, device agnostic platform where they can manage their own private 3D metaverse meeting spaces. Users can host and attend Zoom-like virtual meetings in lifelike virtual reality – with no software downloads – engaging their audiences in a more collaborative and fun way.

Utopia VR has many technology and privacy advantages over solutions built on other metaverse marketplaces such as Horizon Worlds (META) or Decentraland. Utopia VR works on all devices – PC, mobile and virtual reality headsets – whereas many competitors only work in VR or on PC.

Utopia VR is headquartered in Kelowna, B.C.


Utopia VR’s The Metaverse for Everyone™ is a one-click, web-based, avatar-driven, mobile-friendly audio- and video-conferencing platform that utilizes innovative 3D web technology. Utopia VR’s virtual platform works on digital devices including PCs, mobile phones and VR headsets such as Oculus Quest or HTC Vive. No software or proprietary hardware is needed.


Users navigate through the various VRoom environments by using avatars. Users can walk, talk and sit – just like they do in the real world. A user’s avatar can be controlled with a computer keyboard, smartphone or virtual reality headsets. Text chat, voice and video is ever-present and used to communicate with others in the VRoom. For important meetings and presentations, users can also import audio, video, 2D art and images, animated 3D objects, PDF files and their favorite NFTs by simply dragging and dropping files into a VRoom or pasting a video link from supported media platforms.

Organizations that have an existing website can transition their digital assets, including text, images, video, PDFs, slideshows and more, to VRoom environments with a simple copy and paste. This will allow their customers and audiences to experience their brand in a whole new, immersive environment.
Utopia VR’s mobile app enables users to personalize their own 3D environments and then schedule business meetings or social meetups in seconds through a proprietary link management system. The app is available for iPhone and iPad users. The company’s website mirrors the app, which means users can access Utopia VR directly from a PC, laptop, tablet, or VR headset without downloading the app.

Market Outlook

Regarded as the next iteration of the internet, the metaverse is a virtual space where the physical and digital worlds coexist and interact, encompassing virtual reality, augmented reality, extended reality and mixed reality, as well as making use of artificial intelligence and other technologies.

Data consolidator Statista estimated that the global metaverse market size stood at $38.85 billion in 2021 and projected the market would grow to be worth $47.48 billion in 2022. From there, Statista forecasts the value of the metaverse market will explode to reach $678.8 billion by 2030, achieving a CAGR of more than 39% over the period.

The metaverse could create $5 trillion in opportunity by 2030, according to McKinsey & Company.

Management Team

Stuart Gray, President, Co-Founder and director of Utopia VR, has been an officer and director for both private and publicly traded companies and has led public offerings for junior listed companies that have gone on to realize multibillion-dollar market valuations. He previously was a consultant and quarterbacked taking eXp World Holdings Inc. (NASDAQ: EXPI) public. eXp is a disruptive, no bricks and mortar, real estate brokerage firm with 85,000 agents worldwide using its virtual, software-based, metaverse platform for closing transactions, training and events.

Cory Braden, CTO and director of Utopia VR, is a forward-thinking strategic leader with over 20 years of experience in delivering software as a service. Recognized for a positive leadership style and excellent communication skills, he is well-versed in user experience, complex application architectures, cloud infrastructure and management of high-performance teams.

Terry Woloszyn, VP of Sales and Advisory at Utopia VR, brings vast technical and sales experience to the company. Before joining Utopia VR, he conceived and launched a data security startup and graduated from two startup accelerator programs. He has personally raised $20 million in equity venture funding.

Recent News


EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

EverGen (TSX.V: EVGN) (OTCQX: EVGIF) is a leading Canadian renewable energy company that operates fourrevenue-generating assets across three key regions in Canada,alongside two RNG projects currently under construction and oneOntario-based project in development. “Since starting itsoperations and expanding its presence in British Columbia to threeoperating assets, EverGen Infrastructure made a bold decision toexpand its presence nationwide over the past year. In 2022, thecompany broadened its Canadian footprint by acquiring a 67% stakein GrowTEC, an Alberta-based biogas project. EverGen wouldsubsequently go on to purchase a 50% ownership in a large jointventure consisting of three high-quality, on-farm RNG projects inOntario dubbed Project Radius. It is within the latter Greenfieldproject that EverGen Infrastructure could stand to make itsfortunes. Project Radius, located in southern Ontario, is alate-development-stage portfolio of three high-quality, on-farm RNGprojects, collectively capable of producing ~1.7 million GJ/year ofRNG that will contribute to the reduction of emissions fromagricultural operations in southern Ontario,” a recent articlereads. “Today and with over $1 trillion being invested annuallyinto building out clean energy capacity, EverGen InfrastructureCorp finds itself operating at the center of what former Bank ofEngland Governor Mark Carney referred to as the ‘greatestcommercial opportunity of our age.’”

To view the full article, visit

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Friday's trading session at $2.37, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $1.365/$4.00.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Bipartisan congressional legislators have filed a new measure toend the “discriminatory” federal rule that prevents people with prior felonies for drug offenses from owning or operating legal hemp businesses. The “Free to GrowAct,” sponsored by Representatives Chellie Pingree (D-ME), DavidTrone (D-MD), Nancy Mace (R-SC) and Dave Joyce (R-OH), focuses onlyon the section of the 2018 Farm Bill that dealt with priorconvictions and federal legalized hemp. Pingree stated that in spite of legalization, the industry’s expansion is beinghampered by bureaucracy, regulatory uncertainty and discriminatorypolicy. Congress is expected to approve a new farm bill versionthis year. The new legislation would remove provisions from thefarm bill that currently prohibit individuals convicted of a felonydrug offense within the previous 10 years from legally holdingcertain positions within a licensed hemp business. In 2019, the USDA made it clear that only “key participants” — chief executives with a directfinancial stake in the company or other top executives — would besubject to the ban. As a result, employees such as maintenanceworkers are exempt from the rule, which is consistent with thestrict reading that advocates pushed for. The lawmakers are nowattempting to completely remove the prohibitory language. As morepeople are freed from the unwarranted restrictions barring themfrom participating in the hemp industry, it will create downstreamopportunities for enterprises such as Advanced Container Technologies Inc. (OTC: ACTX) engaged in supplying equipment that can be used to grow differentplants indoors, such as cannabis.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.321, even for the day, on 21 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005/$1.25.

Recent News

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

The healthcare industry has been termed “the most heavily targetedindustry for ransomware attacks,” with serious cases increasingfrom 43 in 2016 to 91 in 2021

According to Sophos, cybersecurity attacks in this industryattracted remediation costs of about $1.85 million in 2021, up from$1.27 million in 2020, with the most common disruptions includingdowntime, cancellations of scheduled care, and ambulance diversions

SideChannel recognizes this issue, and through its team of vCISOsit offers top-tier cybersecurity programs specific to thehealthcare sector, ultimately allowing parties to protect theirdata and assets while ensuring the smooth running of dailyoperations

With the growing cases of data breaches worldwide, SideChannel seesa spike in demand for its products and services, and is takingadvantage of the growing cybersecurity market, estimated to hit$266.2 billion by 2027

SideChannel (OTCQB: SDCH), a company on a mission to make cybersecurity simple andaccessible, is constantly evolving its products and services inresponse to the rapidly changing cybersecurity environment. Thishas seen its service offerings expand into a range of industries,including biotech, manufacturing, legal, defense, fintech andothers. In particular, healthcare is a sector currently seeing aspike in cybersecurity attacks, and SideChannel is committed toaddressing this issue.SideChannel (OTCQB: SDCH)is constantly developing ways to better protect its clients. “Itdoes so through its ever-evolving technologies and its move toeducate the masses and sensitize its clients on the evolvingcybersecurity landscape, emerging threats and how to address them.With a team of virtual chief information security officers(‘vCISOs’) offering combined 400-plus years of experience incybersecurity, SideChannel is able to address current globaldemands with solutions to increasing challenges,” a recent articlereads. “SideChannel, through the collective expertise of itsvCISOs, is out to build and lead cybersecurity programs exclusivelyfor small and mid-sized businesses (‘SMBs’). With the increaseduptake of cybersecurity solutions, given the growing need forbusinesses to protect themselves from cyberattacks and comply withregulations, SideChannel is seeing a surge in demand for itsservices. In 2022, it posted $4.8 million in revenue, up from $2.8million in 2021. In addition, the global cybersecurity market isestimated to hit $423.8 billion by 2033, up from $180.2 billion in2022, representing a CAGR of 8.2% over the forecast period(2023-2033)… SideChannel recognizes this opportunity and ispositioning itself as the go-to solution, particularly for SMBs.”To view the full article, visit

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.


Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.


Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Friday's trading session at $0.0799, even for the day, on 700 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0565/$0.18.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reportedadditional findings from its most comprehensive clinical study yet,HYPER-H21-4. “The findings showed that DehydraTECH-CBD resulted ina statistically significant reduction in average baseline serumcatestatin concentrations of 13.50 ng/mL to just 9.65 ng/mL afterfive weeks of dosing, representing a 28.5% drop. In addition, meanarterial pressure significantly dropped by 4.26 ± 1.26 mm/Hgfollowing the five weeks of DehydraTECH-CBD dosing. Nostatistically significant reductions in catestatin concentrationswere identified in the placebo group,” a recent article reads.“Given the growing demand for alternative anti-hypertensivetreatments and therapies, Lexaria recognizes an opportunity andseeks to fill it. These latest results from its ambitiousHYPER-H21-4 study inch the company closer to achieving that goal,ultimately becoming a leader and tapping into a pharmaceuticalmarket that is set to be valued at $34 billion by 2030. Lexaria’smanagement is optimistic that DehydraTECH-CBD and its effectivenessin modulating catestatin levels could become a significant valueenhancer should it eventually enter the marketplace as an approvedhypertension treatment.”

To view the full article, visit

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $2.55, off by 7.2727%, on 26,516 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$4.83.

Recent News

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first andonly 3D-vector electrocardiogram (VECG) platform for heart attackdetection anytime, anywhere, is reporting its operational andfinancial results for the fourth quarter and full year, ended Dec.31, 2022. The company has also scheduled an earnings call andwebcast for today at 4:30 p.m. ET to discuss the report. Ahighlight of the report includes the company’s strategicacquisition of LIVMOR assets, including its FDA-cleared Halo+(TM)Atrial Fibrillation Detection System and physician-prescribedintegrated patient care platform, three U.S. patents, businesscontracts and relationships as well as all Samsung watch and tabletinventory. The report also noted that HeartBeam has partnered withEvolve Manufacturing to build its proprietary AIMIGo 12-Lead 3Dvector electrocardiogram device, has been granted a European patentthat relates to its flagship technology, and has received a patentfor its 12-lead electrocardiogram smartwatch-based monitor; thecompany also cited key personnel changes during the quarter. Thoseinterested in today’s earnings event can access the call by dialing1-877-704-4453 in the United States or 1-201-389-0920internationally, and then using the conference code 13735881. Areplay of the call will also be available two hours after the callis concluded. “In our first year as a public company, 2022 wasfocused on advancing our product launch timeline for the HeartBeamAIMIGo 12-Lead 3D vector electrocardiogram device and HeartBeamAIMI(TM) platform,” said HeartBeam CEO and founder Branislav Vajdicin the press release. “Throughout the fourth quarter and into 2023,our movement toward production and commercialization of ourproducts was underscored by a series of milestones including newacquisitions, partnerships, IP protection and a strengthenedmanagement team. We continue to have strong conviction in ourHeartBeam AIMI software platform technology and HeartBeam AIMIGo,and their potential to offer more accurate heart attack detectionand expedite treatment. As we look toward FDA clearance forHeartBeam AIMI, we are also making significant progress with ourcore HeartBeam AIMIGo product as we prepare for FDA submissionearly this year.”

To view the webcast, visit

To view the full press release, visit

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.


HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Friday's trading session at $2.08, off by 16.6333%, on 130,614 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.12/$6.74.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

On March 9, 2023, a group of nonpartisan Congress legislators penned a letter to senior Biden administration figures asking for transparency on the president’s ongoing review ofmarijuana’s legalization. A draft of the letter was recentlydistributed by Rep. Earl Blumenauer (D-OR) among Congress forsignatures before being sent to Xavier Becerra, secretary of Healthand Human Services (HHS), and Merrick Garland, United Statesattorney general. According to the letter’s content, Biden’s scheduling directive presents a chance to evaluate thecauses and effects of federal law in an open-minded manner. It alsostates that cannabis scheduling was based on prejudice rather thanscience and that it is time to face the fact that cannabis iscurrently a state-regulated drug. The legislators stated thatadministrative descheduling would not absolve Congress of its dutyto enact comprehensive federal marijuana reform owing to the factthat there have been numerous well-considered reform proposalspresented in previous sessions. All of these bills and proposals,according to the letter, aim to honor the state-led initiative thathas been going on for 50 years to reexamine marijuana policy in thecontext of the failed and prejudiced war on drugs. The outcome ofthe ongoing scheduling review could have widespread impacts onvarious companies, such as India Globalization Capital Inc. (NYSE American: IGC), that are seeking to develop medicines from cannabis compoundssuch as THC.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Friday's trading session at $0.3401, off by 4.7739%, on 108,133 volume. The average volume for the last 3 months is 104,114 and the stock's 52-week low/high is $0.2785/$1.16.

Recent News

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F)

The QualityStocks Daily Newsletter would like to spotlight Hillcrest Energy Technologies Ltd. (OTCQB: HLRTF).

Hillcrest (CSE: HEAT) (OTCQB: HLRTF)‘s Zero Voltage Switching (“ZVS”) inverter technology achievesimproved performance of electric systems, with applications atnearly every stage of the electrification ecosystem including cleanenergy industry segments such as wind, solar, energy storage, andelectric vehicle (“EV”) fast chargers. “Traditional inverterspresented mechanical and design challenges, however Hillcrest’s ZVStechnology overcomes those issues with a proprietary approach tosoft switching that achieves increased efficiency, performance andreliability… Hillcrest’s ZVS technology additionally enables smart,grid-forming capabilities of a more distributed, bidirectionalsystem containing a variety of intermittent sources. This isespecially critical to the next generation of grid-tied energysystems that require high-frequency power, including renewableenergy generation, storage, V2X and EV charging infrastructure.Hillcrest’s technology potentially provides additional benefits togrid-connected energy systems by offering a more efficient andreliable means of deploying higher switching frequencies inaddition to improved power quality,” a recent article reads. “Webelieve the industry leading advancements we’ve achieved with ourcore ZVS inverter technology can provide significant,cost-effective efficiency and performance improvements for therapidly expanding markets for zero-emission vehicles and renewableenergy generation and storage systems,” Hillcrest CTO Ari Berger isquoted as saying.

To view the full article, visit

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) is a clean technology company based in Vancouver, British Columbia, engaged in developing high-value, high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems.

From concept to commercialization, Hillcrest invests in the development of energy solutions that power a more sustainable and electrified future. Hillcrest power inverter technology helps produce efficiencies in electrification and maximize the performance of electric systems, including electric vehicles (EV), motors and generators.

The company offers a flexible, single-inverter architecture that can be applied at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of an EV, to provide full-cycle efficiency and performance improvements.

As momentum to electrify and decarbonize energy systems accelerates, Hillcrest believes the power inverter is increasingly emerging as a key component. While system cohorts such as battery packs, PV panels and electric motors are often in the spotlight, the inverter holds the key to unlocking efficiency and performance improvements.

Hillcrest power inverter technology is:

  • REVOLUTIONARY: high-efficiency inverter technology has the potential to revolutionize how motors respond and how efficiency is gained.
  • AGILE: able to deliver and deploy high-efficiency inverter solutions purpose-designed to meet specific customer needs.
  • INNOVATIVE: technology-forward, clean-energy experts who are focused on advancing and optimizing efficient alternative energy use across all electric vehicle and charging platforms.
  • A MARKET LEADER: a next-generation technology provider to the automotive industry’s top suppliers and manufacturers.

Technology & Applications

Hillcrest’s first application for its inverter technology – a 250 kW|800V Hillcrest SiC high efficiency traction inverter – is focused on the growing EV market. Hillcrest technology eliminates traditional design trade-offs faced across the power industry – deploying higher switching frequencies has historically meant a greater increase in losses, lower system efficiency and higher heat. Through a combination of hardware and software expertise, Hillcrest enables power applications to leverage higher switching frequencies AND

  • Realize improved power system performance and reliability
  • Operate at higher power levels without compromising efficiency

The expected benefits of Hillcrest’s traction inverter have been confirmed via testing and shared in a technical white paper, published in April 2022, that confirmed the following results:

  • Significant efficiency gains – 99%-plus inverter efficiency
  • Increased power density targeting 50kW/L+
  • Significantly increased motor efficiency
  • Lower stress on mechanical and electrical parts, enhancing reliability
  • Improved thermal management

Hillcrest has also filed a patent for an enhanced powertrain solution that offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefit of the enhanced powertrain solution is the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless, and bidirectional charging across current and future power levels. Hillcrest sees this as a true EV charging game changer.

The company’s technology applies to nearly every clean energy industry segment:

  • Wind power – an inverter is deployed at a wind turbine generator to convert the AC output, with at least one additional inverter used to deliver the power to the grid/battery.
  • Solar power – an inverter is used to convert the DC output from the photovoltaic panels into the AC power that flows to the grid/battery/home.
  • Energy storage – an inverter is deployed to convert the DC output from the storage system or batteries to the AC power that flows to the grid/home/EV.
  • EV fast chargers – an inverter converts the AC input from the grid/storage system to the DC output needed to charge an EV’s battery.

Market Outlook

According to an April 2022 market analysis by Vantage Market Research (VMR), the global power inverter market is expected to reach a value of $95 billion by 2028, driven by increasing demand for EVs, energy generating wind turbines and solar-powered photovoltaic systems. That jump is forecast from an estimated $70.5 billion market value in 2021 and represents a compound annual growth rate of more than 5%.

According to the VMR report, many governments in countries around the world are supporting alternative options for efficient and nonpolluting energy generation. This has boosted demand for wind energy and solar energy systems. Hillcrest is aiming to capture a share of this future market growth across nearly every segment of the clean energy industry.

Management Team

Don Currie is the founding CEO of Hillcrest Energy Technologies. He has led the company’s successful transition from fossil fuels into clean energy technologies. Earlier in his career, he held various senior level positions, including director, officer and vice president of corporate communications with Enhanced Oil Resources Inc., an oil and gas exploration and production company based in Houston. Prior to that, he worked in other private and public ventures spanning the mining, gaming and technology sectors.

Jamie L. Hogue is the COO of Hillcrest. She brings more than two decades of progressive policy leadership, economic analysis and organizational development experience to Hillcrest. She builds collaborative processes and solutions that drive growing organizations toward a more resilient future. She previously served as the director of operations for Arizona State University’s Ten Across initiative – a compelling observatory positioned on the front lines of economic, social and climate change. She earned a master’s degree in public administration and a bachelor’s degree in economics from Arizona State University.

Ari Berger is Chief Technology Officer at Hillcrest. He brings over a decade of commercial experience with a track record of deploying new electrification technologies and go-to-market strategies. In 2015, he founded NIG Systems Ltd. in Israel, which specializes in custom high performance control systems design. Prior to this, he previously worked for Bental Industries, a leading motor manufacturer. He holds a master’s degree in system control engineering from the Technion – Israel Institute of Technology.

Raj Clair is CFO at Hillcrest. She is a CPA who began her career at Deloitte and has served in advanced finance positions in the energy and resources sector. She has been responsible for reporting, audits and internal controls, as well as working on budgeting and forecasting. She has worked with various publicly listed companies, including SEC registrants, and has both Canadian and U.S. experience. She holds a bachelor’s degree in accounting from Simon Fraser University.

Hillcrest Energy Technologies Ltd. (NASDAQ: HLRTF), closed Friday's trading session at $0.050702, off by 7.8145%, on 5,999 volume. The average volume for the last 3 months is 5,999 and the stock's 52-week low/high is $0.0502/$0.1468.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Friday's trading session at $0.0844, off by 0.118343%, on 144,265 volume. The average volume for the last 3 months is 144,265 and the stock's 52-week low/high is $0.074/$0.17.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.